Skip to content

In the BioHarmony Drug Report Database

Apixaban

Eliquis (apixaban) is a small molecule pharmaceutical. Apixaban was first approved as Eliquis on 2011-05-18. It is used to treat pulmonary embolism and venous thrombosis in the USA. It has been approved in Europe to treat arthroplasty, stroke, and venous thromboembolism. The pharmaceutical is active against coagulation factor X. Eliquis's patents are valid until 2031-02-24 (FDA).
Trade Name Eliquis
Common Name Apixaban
ChEMBL ID CHEMBL231779
Indication arthroplasty, pulmonary embolism, stroke, venous thromboembolism, venous thrombosis
Drug Class Antithrombotic: blood coagulation factor XA inhibitors
Apixaban
Get full access now